Study Immunology and Safety of 60-day Treatment of SQ Grass SLIT (Sublingual Immunotherapy)-Tablet in Adult Subjects With Grass Pollen-induced Allergic Rhinoconjunctivitis

计划入组 107 人 · 首次发布于 2014 年 9 月 19 日

GRASS (Grass MATA MPL Real-world Assessment Study)

计划入组 1,000 人 · 首次发布于 2026 年 2 月 17 日

Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)

计划入组 1,200 人 · 首次发布于 2016 年 8 月 10 日

DAY-301

LASSBio-365

HS-365

Day, Robert

United States

Day One Biopharmaceuticals

United States

NEW DAY DIAGNOSTICS

Nigeria

Bubs Australia Secures Permanent FDA Approval for Three Infant Formula Products in US Market

Bubs Australia Pursues Permanent US Market Access with Clinical Trial

Allergy Therapeutics Secures First German Approval for Grassmuno Grass Pollen Immunotherapy